Stock Traders Buy Large Volume of ADMA Biologics Call Options (NASDAQ:ADMA)

ADMA Biologics, Inc. (NASDAQ:ADMA) was the target of unusually large options trading activity on Monday. Investors purchased 11,474 call options on the company. This represents an increase of approximately 539% compared to the typical volume of 1,797 call options.

Insider Transactions at ADMA Biologics

In related news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Young Kwon sold 60,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the transaction, the director now directly owns 241,441 shares in the company, valued at $4,408,712.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at $36,436,552.94. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 466,900 shares of company stock worth $8,224,121 in the last 90 days. Insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Quest Partners LLC purchased a new position in shares of ADMA Biologics in the 2nd quarter valued at $29,000. Hollencrest Capital Management acquired a new stake in shares of ADMA Biologics during the third quarter worth about $30,000. EntryPoint Capital LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter valued at about $31,000. CWM LLC lifted its holdings in shares of ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 4,367 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in shares of ADMA Biologics in the 2nd quarter valued at about $93,000. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Stock Up 0.3 %

ADMA Biologics stock traded up $0.07 during trading on Monday, reaching $22.69. The stock had a trading volume of 896,935 shares, compared to its average volume of 3,654,469. ADMA Biologics has a 52-week low of $3.60 and a 52-week high of $23.64. The business has a 50 day moving average price of $18.12 and a 200 day moving average price of $13.95. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The stock has a market cap of $5.29 billion, a PE ratio of 161.57 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. During the same period in the previous year, the company earned ($0.02) EPS. The company’s revenue for the quarter was up 78.4% on a year-over-year basis. On average, analysts predict that ADMA Biologics will post 0.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ADMA. HC Wainwright boosted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday. Raymond James upped their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.